GlassScriptPhysician profile
Jonathan M Pargament
NPI 1275848160
$115,844.15
in general payments reported to CMS, 2019-2025
11 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.22 · 2020: $4,697 · 2021: $44K · 2022: $18K · 2023: $24K · 2024: $8,617 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $2,601 · Consulting Fee: $1,050 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,575.00 |
| Food and Beverage | $2,600.90 |
| Consulting Fee | $1,050.00 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $90,344.39 | 2020-2023 | Tepezza |
| Amgen INC. | $24,894.64 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $135.55 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $122.51 | 2025 | Infuse Multifocal |
| Regeneron Healthcare Solutions, INC. | $103.97 | 2023-2024 | Eylea Hd, Eylea |
| Alcon Vision LLC | $98.77 | 2022-2025 | Hydrus Microstent, Clareon |
| Novartis Pharmaceuticals Corporation | $36.64 | 2023 | |
| Lombart Brothers, INC. | $36.22 | 2019 | |
| Halozyme INC | $34.51 | 2024-2025 | Hylenex Recombinant |
| Kerecis Limited | $20.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Genentech USA, INC. | $15.98 | 2024 | Susvimo, Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pargament listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.